Related Experiment Videos
Clonidine suppresses methylxanthine induced quasi-morphine withdrawal syndrome
Abstract:
The effects of the alpha-2 adrenergic agonist, clonidine, on the "quasi-morphine withdrawal syndrome" (QMWS) were examined in drug naive rats. The QMWS was induced by combined systemic administration of iso-butyl-methylxanthine (IBMX: 15 mg/kg, IP) and naloxone (1 mg/kg, IP). Pretreatment with clonidine (50 micrograms/kg, IP) significantly decreased the incidence of 11 out of 16 withdrawal signs. Since clonidine suppresses signs and symptoms of true morphine withdrawal, the suppression of methylxanthine effects demonstrates an additional similarity of the QMWS to true morphine withdrawal. These results suggest that a significant common neural mechanism of both the QMWS and true morphine withdrawal is affected by clonidine.
Insights
Clonidine, an alpha-2 adrenergic agonist, effectively reduced withdrawal symptoms in rats experiencing a quasi-morphine withdrawal syndrome. This suggests clonidine targets common neural mechanisms shared with true morphine withdrawal.
Area of Science:
- Neuroscience
- Pharmacology
- Addiction Research
Background:
- The quasi-morphine withdrawal syndrome (QMWS) serves as a model to study opioid withdrawal.
- Understanding shared mechanisms between QMWS and true morphine withdrawal can inform treatment strategies.
Purpose of the Study:
- To investigate the efficacy of clonidine, an alpha-2 adrenergic agonist, in mitigating QMWS symptoms.
- To explore the potential for shared neural pathways between QMWS and morphine withdrawal.
Main Methods:
- QMWS was induced in drug-naive rats using a combination of iso-butyl-methylxanthine (IBMX) and naloxone.
- Rats were pretreated with clonidine (50 micrograms/kg) before QMWS induction.
- The incidence of 16 distinct withdrawal signs was recorded and analyzed.
Main Results:
- Clonidine pretreatment significantly reduced the occurrence of 11 out of 16 observed withdrawal signs.
- The observed suppression of IBMX-naloxone-induced withdrawal by clonidine mirrors its effects on true morphine withdrawal.
Conclusions:
- Clonidine demonstrates efficacy in reducing symptoms of the QMWS in rats.
- These findings support the hypothesis that clonidine acts on common neural mechanisms involved in both QMWS and true morphine withdrawal.